We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Screening Test Detects Tropical Disease in Blood Donors

By LabMedica International staff writers
Posted on 10 May 2010
A screening test that detects antibodies to a lethal tropical parasite will help safeguard blood for transfusions and tissue and organ recipients.

The test is fully automated, and is highly sensitive and specific for the blood-borne parasite, Trypanosoma cruzi, the causative agent of Chagas diseases. More...
It uses serum or plasma from donors of whole blood or blood components as well as from organ or tissue donors and detects antibodies to T. cruzi. The assay can be used to screen blood from the transplant donor whether the heart is still beating or even if it is not. It is not designed to be used with cord blood.

Manufactured by Abbott Laboratories (Abbot Park, IL, USA), the Abbott Prism Chagas test is a two-step sandwich chemiluminescent assay that uses recombinant parasite antigens coated on microparticles. The test kit also contains anti-human conjugate and alkaline hydrogen peroxide for generating the photons. The test has detected antibodies to the parasite in over 1,000 donors since testing was instituted in 2007.

Reports indicate that 1 in every 27,500 blood donors in the United States will test positive for Chagas Disease. Blood donations in the United States exceed 15 million a year. The test is highly specific and does not react with serum of patients infected with other tropical or sexually transmitted diseases. An estimated 8-11 million people are known to be suffering from Chagas Disease in Mexico, Central and South America. The disease progresses from an acute phase to a chronic one, and is often undetected. The parasite has a predilection for the internal organs, especially the heart.

Karen Midthun, M.D., acting director of the US Food and Drug Administration's Center for Biologics Evaluation and Research, (FDA; Silver Spring, MD, USA), said that "Screening for T. cruzi is an important safety measure to help protect our blood supply and help prevent the spread of Chagas disease." This second-generation test has received FDA approval.

Related Links:
Abbott Laboratories
US Food and Drug Administration



Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
New
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The cell-based tests bring artificial intelligence to transplant outcome care (Photo courtesy of iStock)

AI-Enhanced Cell-Based Blood Tests to Improve Predictive Accuracy for Complex Transplant Outcomes

Managing immunosuppressive drugs in transplant patients is a delicate challenge. Insufficient medication can lead to rejection, which may be cell- or antibody-mediated, while excess immunosuppression raises... Read more

Immunology

view channel
Image: PD-1 protein blockade is the standard treatment for advanced melanoma among the different types of immunotherapy (Photo courtesy of 123RF)

Precision Tool Predicts Immunotherapy Treatment Failure in Melanoma Patients

Melanoma, though accounting for only about 4% of skin tumors, is the deadliest form of skin cancer due to its high potential to metastasize. While immunotherapy, especially PD-1 protein blockade, has revolutionized... Read more

Pathology

view channel
Image: A saliva test can help predict future metabolic health concerns including diabetes and obesity (Photo courtesy of 123RF)

Saliva Test to Enable Early Detection of Diabetes and Obesity

Type 2 diabetes affects about 400 million people globally and is typically diagnosed through elevated blood glucose levels. However, conditions like insulin resistance and hyperinsulinemia may begin developing... Read more

Industry

view channel
Image: Alzheimer’s Association has released its first clinical practice guideline for blood-based biomarker tests (Photo courtesy of Alzheimer’s Association)

New Clinical Guidelines Recommend Use of Blood Tests Instead of Brain Scans for Alzheimer’s Diagnosis

Alzheimer’s disease is a progressive neurodegenerative condition that remains challenging to diagnose early and accurately, particularly in individuals with cognitive impairment. Despite the availability... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.